-
1
-
-
84884474728
-
Pharmacological actions of cannabinoids
-
Springer-Verlag, Heidelberg, Germany
-
R.G. Pertwee, Pharmacological actions of cannabinoids, Handbook of Experimental Pharmacology, vol. 168, Springer-Verlag, Heidelberg, Germany, 2005. pp. 1-51.
-
(2005)
Handbook of Experimental Pharmacology
, vol.168
, pp. 1-51
-
-
Pertwee, R.G.1
-
2
-
-
0346350327
-
The cannabinoid system and immune modulation
-
DOI 10.1189/jlb.0303101
-
T.W. Klein, C. Newton, K. Larsen, L. Lu, I. Perkins, L. Nong, H. Friedman, The cannabinoid system and immune modulation, J. Leukoc. Biol. 74 (2003) 486-496. (Pubitemid 38040375)
-
(2003)
Journal of Leukocyte Biology
, vol.74
, Issue.4
, pp. 486-496
-
-
Klein, T.W.1
Newton, C.2
Larsen, K.3
Lu, L.4
Perkins, I.5
Nong, L.6
Friedman, H.7
-
3
-
-
54049149312
-
Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown
-
E.A. Placzek, Y. Okamoto, N. Ueda, E.L. Barker, Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown, Neuropharmacology 55 (2008) 1095-1104.
-
(2008)
Neuropharmacology
, vol.55
, pp. 1095-1104
-
-
Placzek, E.A.1
Okamoto, Y.2
Ueda, N.3
Barker, E.L.4
-
4
-
-
1842685334
-
Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat
-
DOI 10.1016/j.pain.2004.01.020, PII S030439590400051X
-
D.A. Scott, C.E. Wright, J.A. Angus, Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat, Pain 109 (2004) 124-131. (Pubitemid 38479778)
-
(2004)
Pain
, vol.109
, Issue.1-2
, pp. 124-131
-
-
Scott, D.A.1
Wright, C.E.2
Angus, J.A.3
-
5
-
-
2242490907
-
Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling
-
DOI 10.1126/science.1076535
-
M.H. Bracey, M.A. Hanson, K.R. Masuda, R.C. Stevens, B.F. Cravatt, Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling, Science 298 (2002) 1793-1796. (Pubitemid 35404124)
-
(2002)
Science
, vol.298
, Issue.5599
, pp. 1793-1796
-
-
Bracey, M.H.1
Hanson, M.A.2
Masuda, K.R.3
Stevens, R.C.4
Cravatt, B.F.5
-
6
-
-
0029904838
-
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
-
DOI 10.1038/384083a0
-
B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, N.B. Gilula, Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides, Nature 384 (1996) 83-87. (Pubitemid 26374593)
-
(1996)
Nature
, vol.384
, Issue.6604
, pp. 83-87
-
-
Cravatt, B.F.1
Giang, D.K.2
Mayfield, S.P.3
Boger, D.L.4
Lerner, R.A.5
Gilula, N.B.6
-
7
-
-
0033654202
-
The fatty acid amide hydrolase (FAAH)
-
N. Ueda, R.A. Puffenbarger, S. Yamamoto, D.G. Deutsch, The fatty acid amide hydrolase (FAAH), Chem. Phys. Lipids 108 (2000) 107-121.
-
(2000)
Chem. Phys. Lipids
, vol.108
, pp. 107-121
-
-
Ueda, N.1
Puffenbarger, R.A.2
Yamamoto, S.3
Deutsch, D.G.4
-
8
-
-
20144377098
-
Discovery of a potent, selective, and efficacious class of reversible a-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics
-
DOI 10.1021/jm049614v
-
D.L. Boger, H. Miyauchi, W. Du, C. Hardouin, R.A. Fecik, H. Cheng, I. Hwang, M.P. Hedrick, D. Leung, O. Acevedo, C.R. Guimaraes, W.L. Jorgensen, B.F. Cravatt, Discovery of a potent, selective, and efficacious class of reversible (aketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics, J. Med. Chem. 48 (2005) 1849-1856. (Pubitemid 40396316)
-
(2005)
Journal of Medicinal Chemistry
, vol.48
, Issue.6
, pp. 1849-1856
-
-
Boger, D.L.1
Miyauchi, H.2
Du, W.3
Hardouin, C.4
Fecik, R.A.5
Cheng, H.6
Hwang, I.7
Hedrick, M.P.8
Leung, D.9
Acevedo, O.10
Guimaraes, C.R.W.11
Jorgensen, W.L.12
Cravatt, B.F.13
-
9
-
-
0035979244
-
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
-
DOI 10.1073/pnas.161191698
-
B.F. Cravatt, K. Demarest, M.P. Patricelli, M.H. Bracey, D.K. Giang, B.R. Martin, A.H. Lichtman, Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase, Proc. Natl. Acad. Sci. USA 98 (2001) 9371-9376. (Pubitemid 32743923)
-
(2001)
Proceedings of the National Academy of Sciences of the United States of America
, vol.98
, Issue.16
, pp. 9371-9376
-
-
Cravatt, B.F.1
Demarest, K.2
Patricelli, M.P.3
Bracey, M.H.4
Giang, D.K.5
Martin, B.R.6
Lichtman, A.H.7
-
10
-
-
15744385109
-
Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 30-carbamoyl-biphenyl-3-yl ester (URB597): Effects on anandamide and oleoylethanolamide deactivation
-
DOI 10.1124/jpet.104.078980
-
D. Fegley, S. Gaetani, A. Duranti, A. Tontini, M. Mor, G. Tarzia, D. Piomelli, Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 30-carbamoyl-biphenyl-3-yl ester (URB597): Effects on anandamide and oleoylethanolamide deactivation, J. Pharmacol. Exp. Ther. 313 (2005) 352-358. (Pubitemid 40411361)
-
(2005)
Journal of Pharmacology and Experimental Therapeutics
, vol.313
, Issue.1
, pp. 352-358
-
-
Fegley, D.1
Gaetani, S.2
Duranti, A.3
Tontini, A.4
Mor, M.5
Tarzia, G.6
Piomelli, D.7
-
11
-
-
67650732783
-
Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders
-
K. Ahn, D.S. Johnson, B.F. Cravatt, Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders, Expert Opin. Drug Discov. 4 (2009) 763-784.
-
(2009)
Expert Opin. Drug Discov.
, vol.4
, pp. 763-784
-
-
Ahn, K.1
Johnson, D.S.2
Cravatt, B.F.3
-
12
-
-
0036221971
-
CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain
-
DOI 10.1016/S0304-3959(01)00454-7, PII S0304395901004547
-
N. Clayton, F.H. Marshall, C. Bountra, C.T. O'Shaughnessy, CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain, Pain 96 (2002) 253-260. (Pubitemid 34327871)
-
(2002)
Pain
, vol.96
, Issue.3
, pp. 253-260
-
-
Clayton, N.1
Marshall, F.H.2
Bountra, C.3
O'Shaughnessy, C.T.4
-
13
-
-
2342498975
-
2 receptor partial agonist with antihyperalgesic and antiallodynic effects
-
DOI 10.1124/jpet.103.062836
-
J. De Vry, D. Denzer, E. Reissmueller, M. Eijckenboom, M. Heil, H. Meier, F. Mauler, 3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1- butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects, J. Pharmacol. Exp. Ther. 310 (2004) 620-632. (Pubitemid 38988907)
-
(2004)
Journal of Pharmacology and Experimental Therapeutics
, vol.310
, Issue.2
, pp. 620-632
-
-
De Vry, J.1
Denzer, D.2
Reissmueller, E.3
Eijckenboom, M.4
Heil, M.5
Meier, H.6
Mauler, F.7
-
14
-
-
12944263838
-
2, a peripheral cannabinoid receptor
-
2, a peripheral cannabinoid receptor, Proc. Natl. Acad. Sci. USA 96 (1999) 14228-14233.
-
(1999)
Proc. Natl. Acad. Sci. USA
, vol.96
, pp. 14228-14233
-
-
Hanus, L.1
Breuer, A.2
Tchilibon, S.3
Shiloah, S.4
Goldenberg, D.5
Horowitz, M.6
Pertwee, R.G.7
Ross, R.A.8
Mechoulam, R.9
Fride, E.10
-
15
-
-
0038582327
-
A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain
-
DOI 10.1016/S0304-3959(02)00450-5
-
L.J. Kehl, D.T. Hamamoto, P.W. Wacnik, D.L. Croft, B.D. Norsted, G.L. Wilcox, D.A. Simone, A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain, Pain 103 (2003) 175-186. (Pubitemid 36579097)
-
(2003)
Pain
, vol.103
, Issue.1-2
, pp. 175-186
-
-
Kehl, L.J.1
Hamamoto, D.T.2
Wacnik, P.W.3
Croft, D.L.4
Norsted, B.D.5
Wilcox, G.L.6
Simone, D.A.7
-
16
-
-
0032056333
-
9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats
-
DOI 10.1016/S0091-3057(97)00583-2, PII S0091305797005832
-
F.L. Smith, K. Fujimori, J. Lowe, S.P. Welch, Characterization of δ9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats, Pharmacol. Biochem. Behav. 60 (1998) 183-191. (Pubitemid 28236629)
-
(1998)
Pharmacology Biochemistry and Behavior
, vol.60
, Issue.1
, pp. 183-191
-
-
Smith, F.L.1
Fujimori, K.2
Lowe, J.3
Welch, S.P.4
-
17
-
-
32244432341
-
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models
-
DOI 10.1038/sj.bjp.0706510, PII 0706510
-
A. Jayamanne, R. Greenwood, V.A. Mitchell, S. Aslan, D. Piomelli, C.W. Vaughan, Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models, Br. J. Pharmacol. 147 (2006) 281-288. (Pubitemid 43214685)
-
(2006)
British Journal of Pharmacology
, vol.147
, Issue.3
, pp. 281-288
-
-
Jayamanne, A.1
Greenwood, R.2
Mitchell, V.A.3
Aslan, S.4
Piomelli, D.5
Vaughan, C.W.6
-
18
-
-
0028108312
-
Inhibitors of arachidonoyl ethanolamide hydrolysis
-
B. Koutek, G.D. Prestwich, A.C. Howlett, S.A. Chin, D. Salehani, N. Akhavan, D.G. Deutsch, Inhibitors of arachidonoyl ethanolamide hydrolysis, J. Biol. Chem. 269 (1994) 22937-22940. (Pubitemid 24283267)
-
(1994)
Journal of Biological Chemistry
, vol.269
, Issue.37
, pp. 22937-22940
-
-
Koutek, B.1
Prestwich, G.D.2
Howlett, A.C.3
Chin, S.A.4
Salehani, D.5
Akhavan, N.6
Deutsch, D.G.7
-
19
-
-
36048978697
-
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity
-
DOI 10.1021/bi701378g
-
K. Ahn, D.S. Johnson, L.R. Fitzgerald, M. Liimatta, A. Arendse, T. Stevenson, E.T. Lund, R.A. Nugent, T.K. Nomanbhoy, J.P. Alexander, B.F. Cravatt, Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity, Biochemistry 46 (2007) 13019-13030. (Pubitemid 350086220)
-
(2007)
Biochemistry
, vol.46
, Issue.45
, pp. 13019-13030
-
-
Ahn, K.1
Johnson, D.S.2
Fitzgerald, L.R.3
Liimatta, M.4
Arendse, A.5
Stevenson, T.6
Lund, E.T.7
Nugent, R.A.8
Nomanbhoy, T.K.9
Alexander, J.P.10
Cravatt, B.F.11
-
20
-
-
64749114255
-
Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain
-
K. Ahn, D.S. Johnson, M. Mileni, D. Beidler, J.Z. Long, M.K. McKinney, E. Weerapana, N. Sadagopan, M. Liimatta, S.E. Smith, S. Lazerwith, C. Stiff, S. Kamtekar, K. Bhattacharya, Y. Zhang, S. Swaney, K. Van Becelaere, R.C. Stevens, B.F. Cravatt, Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain, Chem. Biol. 16 (2009) 411-420.
-
(2009)
Chem. Biol.
, vol.16
, pp. 411-420
-
-
Ahn, K.1
Johnson, D.S.2
Mileni, M.3
Beidler, D.4
Long, J.Z.5
McKinney, M.K.6
Weerapana, E.7
Sadagopan, N.8
Liimatta, M.9
Smith, S.E.10
Lazerwith, S.11
Stiff, C.12
Kamtekar, S.13
Bhattacharya, K.14
Zhang, Y.15
Swaney, S.16
Van Becelaere, K.17
Stevens, R.C.18
Cravatt, B.F.19
-
21
-
-
79959506821
-
Mechanistic and pharmacological characterization of PF-04457845: A highly potent and selective FAAH inhibitor that reduces inflammatory and noninflammatory pain
-
K. Ahn, S.E. Smith, M.B. Liimatta, D. Beidler, N. Sadagopan, D.T. Dudley, T. Young, P. Wren, Y. Zhang, S. Swaney, K. Van Becelaere, J.L. Blankman, D.K. Nomura, S.N. Bhattachar, C. Stiff, T.K. Nomanbhoy, E. Weerapana, D.S. Johnson, B.F. Cravatt, Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective FAAH inhibitor that reduces inflammatory and noninflammatory pain, J. Pharmacol. Exp. Ther. 338 (2011) 114-124.
-
(2011)
J. Pharmacol. Exp. Ther.
, vol.338
, pp. 114-124
-
-
Ahn, K.1
Smith, S.E.2
Liimatta, M.B.3
Beidler, D.4
Sadagopan, N.5
Dudley, D.T.6
Young, T.7
Wren, P.8
Zhang, Y.9
Swaney, S.10
Van Becelaere, K.11
Blankman, J.L.12
Nomura, D.K.13
Bhattachar, S.N.14
Stiff, C.15
Nomanbhoy, T.K.16
Weerapana, E.17
Johnson, D.S.18
Cravatt, B.F.19
-
22
-
-
65349167368
-
Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH)
-
D.S. Johnson, K. Ahn, S. Kesten, S.E. Lazerwith, Y. Song, M. Morris, L. Fay, T. Gregory, C. Stiff, J.B. Dunbar Jr., M. Liimatta, D. Beidler, S. Smith, T.K. Nomanbhoy, B.F. Cravatt, Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH), Bioorg. Med. Chem. Lett. 19 (2009) 2865-2869.
-
(2009)
Bioorg. Med. Chem. Lett.
, vol.19
, pp. 2865-2869
-
-
Johnson, D.S.1
Ahn, K.2
Kesten, S.3
Lazerwith, S.E.4
Song, Y.5
Morris, M.6
Fay, L.7
Gregory, T.8
Stiff, C.9
Dunbar Jr., J.B.10
Liimatta, M.11
Beidler, D.12
Smith, S.13
Nomanbhoy, T.K.14
Cravatt, B.F.15
-
23
-
-
79951518976
-
Discovery of PF-04457845: A highly potent, orally bioavailable, and selective urea FAAH inhibitor
-
D.S. Johnson, C. Stiff, S.E. Lazerwith, S.R. Kesten, L.K. Fay, M. Morris, D. Beidler, M.B. Liimatta, S.E. Smith, D.T. Dudley, N. Sadagopan, S.N. Bhattachar, S.J. Kesten, T.K. Nomanbhoy, B.F. Cravatt, K. Ahn, Discovery of PF-04457845: a highly potent, orally bioavailable, and selective urea FAAH inhibitor, ACS Med. Chem. Lett. 2 (2011) 91-96.
-
(2011)
ACS Med. Chem. Lett.
, vol.2
, pp. 91-96
-
-
Johnson, D.S.1
Stiff, C.2
Lazerwith, S.E.3
Kesten, S.R.4
Fay, L.K.5
Morris, M.6
Beidler, D.7
Liimatta, M.B.8
Smith, S.E.9
Dudley, D.T.10
Sadagopan, N.11
Bhattachar, S.N.12
Kesten, S.J.13
Nomanbhoy, T.K.14
Cravatt, B.F.15
Ahn, K.16
-
24
-
-
70349199021
-
Structure based design of novel irreversible FAAH inhibitors
-
J.L. Wang, S.J. Bowen, B.A. Schweitzer, H.M. Madsen, J. McDonald, M.J. Pelc, R.E. Tenbrink, D. Beidler, A. Thorarensen, Structure based design of novel irreversible FAAH inhibitors, Bioorg. Med. Chem. Lett. 19 (2009) 5970-5974.
-
(2009)
Bioorg. Med. Chem. Lett.
, vol.19
, pp. 5970-5974
-
-
Wang, J.L.1
Bowen, S.J.2
Schweitzer, B.A.3
Madsen, H.M.4
McDonald, J.5
Pelc, M.J.6
Tenbrink, R.E.7
Beidler, D.8
Thorarensen, A.9
-
25
-
-
0027078685
-
Isolation and structure of a brain constituent that binds to the cannabinoid receptor
-
W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, R. Mechoulam, Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science 258 (1992) 1946-1949. (Pubitemid 23026736)
-
(1992)
Science
, vol.258
, Issue.5090
, pp. 1946-1949
-
-
Devane, W.A.1
Hanus, L.2
Breuer, A.3
Pertwee, R.G.4
Stevenson, L.A.5
Griffin, G.6
Gibson, D.7
Mandelbaum, A.8
Etinger, A.9
Mechoulam, R.10
-
26
-
-
67649371450
-
Endogenous ethanolamide analysis in human plasma using HPLC tandem MS with electrospray ionization
-
J. Palandra, J. Prusakiewicz, J.S. Ozer, Y. Zhang, T.G. Heath, Endogenous ethanolamide analysis in human plasma using HPLC tandem MS with electrospray ionization, J. Chromatogr. B 877 (2009) 2052-2060.
-
(2009)
J. Chromatogr. B
, vol.877
, pp. 2052-2060
-
-
Palandra, J.1
Prusakiewicz, J.2
Ozer, J.S.3
Zhang, Y.4
Heath, T.G.5
-
27
-
-
3242664227
-
A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase
-
DOI 10.1016/j.jbbm.2004.04.020, PII S0165022X04001162
-
L. Boldrup, S.J. Wilson, A.J. Barbier, C.J. Fowler, A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase, J. Biochem. Biophys. Methods 60 (2004) 171-177. (Pubitemid 38953060)
-
(2004)
Journal of Biochemical and Biophysical Methods
, vol.60
, Issue.2
, pp. 171-177
-
-
Boldrup, L.1
Wilson, S.J.2
Barbier, A.J.3
Fowler, C.J.4
-
28
-
-
0033557834
-
A sensitive and specific radiochromatographic assay of fatty acid amide hydrolase activity
-
DOI 10.1006/abio.1998.2964
-
M. Maccarrone, M. Bari, A.F. Agro, A sensitive and specific radiochromatographic assay of fatty acid amide hydrolase activity, Anal. Biochem. 267 (1999) 314-318. (Pubitemid 29095878)
-
(1999)
Analytical Biochemistry
, vol.267
, Issue.2
, pp. 314-318
-
-
Maccarrone, M.1
Bari, M.2
Finazzi, A.A.3
-
29
-
-
23744501056
-
Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: Evidence that VDM11 acts as an FAAH substrate
-
DOI 10.1038/sj.bjp.0706253
-
S. Vandevoorde, C.J. Fowler, Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate, Br. J. Pharmacol. 145 (2005) 885-893. (Pubitemid 41129010)
-
(2005)
British Journal of Pharmacology
, vol.145
, Issue.7
, pp. 885-893
-
-
Vandevoorde, S.1
Fowler, C.J.2
-
30
-
-
32544451155
-
Fit-for-purpose method development and validation for successful biomarker measurement
-
DOI 10.1007/s11095-005-9045-3
-
J.W. Lee, V. Devanarayan, Y.C. Barrett, R. Weiner, J. Allinson, S. Fountain, S. Keller, I. Weinryb, M. Green, L. Duan, J.A. Rogers, R. Millham, P.J. O'Brien, J. Sailstad, M. Khan, C. Ray, J.A. Wagner, Fit-for-purpose method development and validation for successful biomarker measurement, Pharm. Res. 23 (2006) 312-328. (Pubitemid 43237862)
-
(2006)
Pharmaceutical Research
, vol.23
, Issue.2
, pp. 312-328
-
-
Lee, J.W.1
Devanarayan, V.2
Barrett, Y.C.3
Weiner, R.4
Allinson, J.5
Fountain, S.6
Keller, S.7
Weinryb, I.8
Green, M.9
Duan, L.10
Rogers, J.A.11
Millham, R.12
O'Brien, P.J.13
Sailstad, J.14
Khan, M.15
Ray, C.16
Wagner, J.A.17
-
31
-
-
0003484310
-
-
Food and Drug Administration, FDA, U.S. Department of Health and Human Services, Rockville, MD
-
Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation. FDA, U.S. Department of Health and Human Services, Rockville, MD, 2001.
-
(2001)
Guidance for Industry: Bioanalytical Method Validation
-
-
-
32
-
-
67649854862
-
Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol
-
M.L. Yates, E.L. Barker, Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol, Mol. Pharmacol. 76 (2009) 11-17.
-
(2009)
Mol. Pharmacol.
, vol.76
, pp. 11-17
-
-
Yates, M.L.1
Barker, E.L.2
|